Emerging Growth Research Issues Company-Sponsored Research Flash Report ...

(PR-inside.com) NEW YORK CITY, NY / ACCESS Newswire / August 27, 2026 / Emerging Growth Research, LLC ("Emerging Growth Research" or "EGR") today announced the release of its company-sponsored research flash report on OSR Health, Inc. (NASDAQ:OSRH), a global healthcare holding company advancing oral immunotherapies for cancer and age-related disease, non-invasive glucose monitoring technology, and fourth-party logistics (4PL) operations. This release is being issued as an updated version of EGR's previously published press release. The updated release is intended to clarify the company-sponsored nature of the research and provide additional disclosure regarding EGR's financial relationship with the Company. The flash report highlights OSRH's ..

Emerging Growth Research Issues Company-Sponsored Research Flash Report on OSR Health, Inc.

Before Recommending an International Student Health Insurance Company: What Five U.S. Universities Actually Require in 2026–2027

SpyGlass Pharma Celebrates Grand Opening of New Irvine Headquarters, Positioning Itself for First Product Launch and Custom R&D Space

Future portfolio expansion will advance a new era of ophthalmic care while driving continued growth of Irvine's MedTech and life sciences sector. IRVINE, Calif., Aug. 27, 2026 /PRNewswire/ -- SpyGlass Pharma, a biopharmaceutical clinical-stage company dedicated to transforming treatment...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Hims & Hers Health, Inc. - HIMS

NEW YORK, Aug. 27, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Hims & Hers Health, Inc. ("Hims" or the "Company") (NYSE: HIMS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The...

Advanced Recovery Systems and Promises Behavioral Health Combine to Advance Behavioral Health Care Delivery

Advanced Recovery Systems and Promises Behavioral Health have combined, bringing together two organizations focused on evidence-based, compassionate care for people experiencing addiction and mental health conditions. [PR.com]

Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccine

NEW YORK and MAINZ, GERMANY, August 27, 2026 — Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for the companies’ 2026-2027 COVID-19 vaccine formula targeting the XFG variant (COMIRNATY ® XFG; COVID-19 Vaccine, mRNA) for use in adults ages 65 years and older, as well as in individuals ages 5 through 64 years with at least one underlying condition that puts them at high risk for severe outcomes from COVID-19. 1

Vanta Announces Engagement of Independent Trading Group for Market-Making ...

(PR-inside.com) VANCOUVER, BC / ACCESS Newswire / August 27, 2026 /Vanta Holdings Inc. (CSE:VNTA)(OTC:VNTXF)(FSE:7BC, WKN:A4205J) ("Vanta" or the "Company"), a consumer health sciences and longevity company focused on preventative wellness and healthspan extension, and parent of the Vanta premium longevity brand, announces that it has engaged the services of Independent Trading Group (ITG) Inc. ("ITG") to provide market-making services in accordance with Canadian Securities Exchange ("CSE") policies, effective August 27, 2026. The engagement of ITG forms part of the Company's broader strategic capital markets initiatives, aimed at enhancing trading liquidity, supporting orderly market conditions, and improving overall market quality for the Company's ..

IQVIA Wins Multiple Industry Awards for AI and Technology Innovation Across Life Sciences and Healthcare

RESEARCH TRIANGLE PARK, N.C., August 27, 2026--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, today announced it received recognition this year from multiple independent industry awards programs for its use of AI to help healthcare and life sciences organizations improve decisions, strengthen regulated workflows, protect patient privacy and optimize clinical trial execution

Moderna Receives U.S. FDA Approval for Updated 2026-2027 COVID-19 Vaccines ...

(PR-inside.com) CAMBRIDGE, MA / ACCESS Newswire / August 27, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Applications (sBLA) for the 2026-2027 formulas for Spikevax® (COVID-19 Vaccine, mRNA) and mNEXSPIKE® (COVID-19 Vaccine, mRNA), containing the JN.1-lineage XFG subvariant of SARS-CoV-2 to help prevent COVID-19. The updated formula for Spikevax is now approved for individuals 6 months through 64 years of age with at least one underlying condition placing them at high risk for severe outcomes from COVID-19, and all adults 65 years of age and older. mNEXSPIKE, Moderna's latest ..

Moderna Receives U.S. FDA Approval for Updated 2026-2027 COVID-19 Vaccines

American College of Lifestyle Medicine Annual Conference to highlight lifestyle medicine implementation, clinical value and successful behavior change

The American College of Lifestyle Medicine (ACLM) has announced a full lineup of 145 keynote and concurrent sessions for its accredited, hybrid 2026 Lifestyle Medicine Annual Conference, set for November 8 to 11. The event presentations will showcase implementation of lifestyle medicine...